Wednesday, July 8, 2026

Drug profile · INN

latanoprostene bunod

latanoprostene bunod (LATANOPROSTENE BUNOD) is a prostanoid fp receptor agonist. Route of administration: ophthalmic. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — latanoprostene bunod
US status
approved
Class
Route
OPHTHALMIC
Patents
0
Programs
0
Data quality
0.84

Quick answer

latanoprostene bunod (LATANOPROSTENE BUNOD) is a prostanoid fp receptor agonist. Route of administration: ophthalmic. Current US regulatory status: approved.

Key facts

INN latanoprostene bunod
Brand LATANOPROSTENE BUNOD
Mechanism Prostanoid FP receptor agonist
Target Prostaglandin F2-alpha receptor
Route OPHTHALMIC
Formulation SOLUTION/DROPS

Mechanism of action

Prostanoid FP receptor agonist

Primary target: Prostaglandin F2-alpha receptor

Approval history

Authority Status Date
FDA approved

Related & competitor drugs

  1. bimatoprost Sensory organs (S01)
  2. carboprost tromethamine Prostanoid FP receptor agonist
  3. dinoprost tromethamine Prostanoid FP receptor agonist
  4. latanoprost Sensory organs (S01)
  5. tafluprost Prostanoid FP receptor agonist
  6. travoprost Sensory organs (S01)

Frequently asked questions

What is latanoprostene bunod?

latanoprostene bunod (LATANOPROSTENE BUNOD) is a prostanoid fp receptor agonist. Route of administration: ophthalmic. Current US regulatory status: approved.

What is the brand name for latanoprostene bunod?

LATANOPROSTENE BUNOD is a marketed brand name for latanoprostene bunod. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of latanoprostene bunod?

latanoprostene bunod has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.